Pemphigus
Drug research and approvals for pemphigus: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 19, 2026, 11 studies of pemphigus are recruiting on ClinicalTrials.gov, Health Canada has authorized 2 drug trials for it since 2013, and FDA has 1 approved and 7 open orphan designations naming it.
- Recruiting worldwide: 11
- Trials authorized in Canada: 2
- FDA orphan approvals: 1
- EU medicines: 0
- Gut Microbiome Diversity in Adults With Inflammatory and Immune-Mediated Skin DiseasesNCT07944196 · Not reported · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · starts Apr 11, 2026
- A Study to Investigate Safety and Efficacy of KB111 for the Treatment of Hailey-Hailey DiseaseNCT07717346 · Early Phase 1 · Krystal Biotech, Inc. · starts May 6, 2026
- CD19 CAR-T Therapy for Refractory Pemphigus VulgarisNCT07681388 · Not applicable · Jinbo Chen · starts Jan 15, 2026
- Comparison of the Efficacy of Clobetasol Propionate 0.05% Mouthwash, Photobiomodulation, and Their Combination in…NCT07641725 · Not applicable · Damascus University · starts Nov 1, 2025
- Efficacy of Guselkumab in Treating Hailey Hailey DiseaseNCT06651489 · Phase 2 · Yale University · starts Mar 13, 2025
- Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell…NCT06581562 · Phase 1 · IRIS Research and Development, LLC · starts May 15, 2024
- A Clinical Study of B007 in the Treatment of Pemphigus.NCT06454357 · Phase 2 / Phase 3 · Shanghai Jiaolian Drug Research and Development Co., Ltd · starts Jul 12, 2024
- FARD (RaDiCo Cohort) (RaDiCo-FARD)NCT05954416 · Not reported · Institut National de la Santé Et de la Recherche Médicale, France · starts Mar 7, 2018
- Comparison of a Personalized Maintenance Therapy With the Standard Treatment in PemphigusNCT05898308 · Phase 4 · University Hospital, Rouen · starts Dec 4, 2024
Approved 4
- RituximabB-lymphocyte antigen CD20 binding agent
- PrednisoneGlucocorticoid receptor agonist
- DexamethasoneGlucocorticoid receptor agonist
- Dexamethasone phosphoric acidGlucocorticoid receptor agonist
Phase 3 7
- Mycophenolate mofetilInosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
- CyclophosphamideDNA inhibitor
- AcetaminophenCyclooxygenase inhibitor
- OfatumumabB-lymphocyte antigen CD20 binding agent
- CetirizineHistamine H1 receptor antagonist
- Triamcinolone acetonideGlucocorticoid receptor agonist
- RilzabrutinibTyrosine-protein kinase BTK inhibitor
Phase 2 9
- AzathioprineAmidophosphoribosyltransferase inhibitor
- EtanerceptTNF-alpha inhibitor
- InfliximabTNF-alpha inhibitor
- Human immunoglobulin gReplacement therapy, immunomodulatory effects
- FilgrastimGranulocyte colony stimulating factor receptor agonist
- DapsoneDihydropteroate synthase 1 inhibitor
- ITX-5061 free baseMAP kinase p38 alpha inhibitor
- IanalumabTumor necrosis factor receptor superfamily member 13C binding agent
- ParsaclisibPI3-kinase p110-delta subunit inhibitor
Phase 1 or earlier 4
- OrilanolimabIgG receptor FcRn large subunit p51 antagonist
- PI-0824
- BatoclimabIgG receptor FcRn large subunit p51 inhibitor
- SirolimusFK506-binding protein 1A inhibitor
How its trials ended
63 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 20 whose ending is known, 25% met their primary endpoint, 10% missed it and 65% stopped early.
- Completed, result not reported1625%
- Status unknown1524%
- Ongoing1219%
- Stopped: sponsor or business decision610%
- Met its primary endpoint58%
- Stopped: other or unclear35%
- Missed its primary endpoint23%
- Stopped: enrollment or feasibility23%
- Stopped: lack of efficacy12%
- Stopped: funding12%
| Feb 28, 2019 | A randomized, double-blind, placebo-controlled, multicenter trial to evaluate the efficacy and safety of oral btk inhibitor PRN1008 in moderate to severe…Rilzabrutinib (PRN1008) / Rituximab | Principia Biopharma Inc | Closed |
| May 14, 2015 | "a randomized, double-blind, double-dummy, active-comparator, multicenter study to evaluate the efficacy and safety of rituximab versus mmf in patients with…Rituxan / Cellcept | Roche | Ongoing |
| Jun 7, 2018 | Rituxan(r); MabThera(r)RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris. | Genentech, Inc. | Approved |
| Aug 20, 2026 | Bispecific humanized IgG4 BCMA-directed CD3 T cell engager…Treatment of pemphigus | Ouro Medicines Ltd. | Designated |
| Mar 14, 2026 | Resecabtagene autoleucelTreatment of pemphigus vulgaris | Cabaletta Bio, Inc. | Designated |
| Oct 16, 2025 | AfamelanotideTreatment of pemphigus | Wanbangde Pharmaceutical Group Co., Ltd. | Designated |
| Jan 28, 2020 | Autologous Desmoglein 3 (DSG3) Chimeric Autoantibody…Treatment of pemphigus vulgaris | Cabaletta Bio, Inc. | Designated |
| May 14, 2014 | AfamelanotideTreatment of familial benign chronic pemphigus (Hailey-Hailey disease) | Clinuvel, Inc. | Designated |
| May 26, 2006 | Mycophenolate mofetilTreatment of pemphigus vulgaris | Hoffman-La Roche, Inc. | Designated |
| Oct 26, 2004 | Desmoglein 3 synthetic peptide (PI-0824)Treatment of pemphigus vulgaris | Peptimmune, Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA